Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans

Main Article Content

Panagiotis Zagaliotis
Jordyn Michalik-Provasek
Jason J. Gill
Thomas Walsh

Abstract

Drug-resistant Gram-negative bacterial pathogens are an increasingly serious health threat causing worldwide nosocomial infections with high morbidity and mortality. Of these, the most prevalent and severe are Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Salmonella typhimurium. The extended use of antibiotics has led to the emergence of multidrug resistance in these bacteria. Drug-inactivating enzymes produced by these bacteria, as well as other resistance mechanisms, render drugs ineffective and make treatment of such infections more difficult and complicated. This makes the development of novel antimicrobial agents an urgent necessity. Bacteriophages, which are bacteria-killing viruses first discovered in 1915, have been used as therapeutic antimicrobials in the past, but their use was abandoned due to the widespread availability of antibiotics in the 20th century. The emergence, however, of drug-resistant pathogens has re-affirmed the need for bacteriophages as therapeutic strategies. This review describes the use of bacteriophages as novel agents to combat this rapidly emerging public health crisis by comprehensively enumerating and discussing the innovative use of bacteriophages in both animal models and in patients infected by Gram-negative bacteria.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Zagaliotis P, Michalik-Provasek J, Gill J, Walsh T. Therapeutic Bacteriophages for Gram-Negative Bacterial Infections in Animals and Humans. PAI [Internet]. 2022 Oct. 17 [cited 2022 Nov. 30];7(2):1-45. Available from: https://www.paijournal.com/index.php/paijournal/article/view/516
Section
Reviews

References

1. Dhingra S, Rahman NAA, Peile E, Rahman M, Sartelli M, Hassali MA, Islam T, Islam S, Haque M. Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter. Front Public Health. 2020;8:535668. doi: 10.3389/fpubh.2020.535668. PubMed PMID: 33251170; PMCID: PMC7672122.

2. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417-33. doi: 10.1128/MMBR.00016-10. PubMed PMID: 20805405; PMCID: PMC2937522.

3. Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, Heeg P, Ilschner C, Kramer A, Larson E, Merkens W, Mielke M, Oltmanns P, Ross B, Rotter M, Schmithausen RM, Sonntag HG, Trautmann M. Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05. doi: 10.3205/dgkh000290. PubMed PMID: 28451516; PMCID: PMC5388835.

4. World Health O. Antibiotic resistance: multi-country public awareness survey. Geneva: World Health Organization; 2015.

5. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018;66(8):1290-7. doi: 10.1093/cid/cix893. PubMed PMID: 29165604; PMCID: PMC5884739.

6. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4(3):482-501. doi: 10.3934/microbiol.2018.3.482. PubMed PMID: 31294229; PMCID: PMC6604941.

7. Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics (Basel). 2022;11(6). doi: 10.3390/antibiotics11060723. PubMed PMID: 35740130; PMCID: PMC9220290.

8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. PubMed PMID: 21793988.

9. Mohapatra DP, Debata NK, Singh SK. Extensively drug-resistant and pandrug-resistant Gram-negative bacteria in a tertiary-care hospital in Eastern India: A 4-year retrospective study. J Glob Antimicrob Resist. 2018;15:246-9. doi: 10.1016/j.jgar.2018.08.010. PubMed PMID: 30144638.

10. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res. 2005;36(6):697-705. doi: 10.1016/j.arcmed.2005.06.009. PubMed PMID: 16216651.

11. Twort FW. An Investigation on the Nature of Ultra-Microscopic Viruses. Lancet. 1915;186(4814):1241-3. doi: 10.1016/s0140-6736(01)20383-3.

12. Keen EC. A century of phage research: bacteriophages and the shaping of modern biology. Bioessays. 2015;37(1):6-9. doi: 10.1002/bies.201400152. PubMed PMID: 25521633; PMCID: PMC4418462.

13. Fernandes S, Sao-Jose C. Enzymes and Mechanisms Employed by Tailed Bacteriophages to Breach the Bacterial Cell Barriers. Viruses. 2018;10(8). doi: 10.3390/v10080396. PubMed PMID: 30060520; PMCID: PMC6116005.

14. Jasim HN, Hafidh RR, Abdulamir AS. Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study. Iran J Basic Med Sci. 2018;21(11):1100-8. doi: 10.22038/IJBMS.2018.27307.6665. PubMed PMID: 30483382; PMCID: PMC6251394.

15. Wang C, Li P, Niu W, Yuan X, Liu H, Huang Y, An X, Fan H, Zhangxiang L, Mi L, Zheng J, Liu Y, Tong Y, Mi Z, Bai C. Protective and therapeutic application of the depolymerase derived from a novel KN1 genotype of Klebsiella pneumoniae bacteriophage in mice. Res Microbiol. 2019;170(3):156-64. doi: 10.1016/j.resmic.2019.01.003. PubMed PMID: 30716390.

16. Lin H, Paff ML, Molineux IJ, Bull JJ. Therapeutic Application of Phage Capsule Depolymerases against K1, K5, and K30 Capsulated E. coli in Mice. Front Microbiol. 2017;8:2257. doi: 10.3389/fmicb.2017.02257. PubMed PMID: 29201019; PMCID: PMC5696595.

17. Mushtaq N, Redpath MB, Luzio JP, Taylor PW. Treatment of experimental Escherichia coli infection with recombinant bacteriophage-derived capsule depolymerase. J Antimicrob Chemother. 2005;56(1):160-5. doi: 10.1093/jac/dki177. PubMed PMID: 15914489.

18. Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11(1):2-14. doi: 10.2174/138920110790725311. PubMed PMID: 20214604.

19. El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans. Clin Infect Dis. 2019;69(1):167-78. doi: 10.1093/cid/ciy947. PubMed PMID: 30395179.

20. Kortright KE, Chan BK, Koff JL, Turner PE. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe. 2019;25(2):219-32. doi: 10.1016/j.chom.2019.01.014. PubMed PMID: 30763536.

21. Bielen K, s Jongers B, Malhotra-Kumar S, Jorens PG, Goossens H, Kumar-Singh S. Animal models of hospital-acquired pneumonia: current practices and future perspectives. Ann Transl Med. 2017;5(6):132. doi: 10.21037/atm.2017.03.72. PubMed PMID: 28462212; PMCID: PMC5395468.

22. Waack U, Weinstein EA, Farley JJ. Assessing Animal Models of Bacterial Pneumonia Used in Investigational New Drug Applications for the Treatment of Bacterial Pneumonia. Antimicrob Agents Chemother. 2020;64(5). doi: 10.1128/AAC.02242-19. PubMed PMID: 32122895; PMCID: PMC7179594.

23. Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y, Xu M, Guo X, Hu F, He P. Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant Acinetobacter baumannii in Mice. Front Microbiol. 2017;8:2659. doi: 10.3389/fmicb.2017.02659. PubMed PMID: 29375524; PMCID: PMC5767256.

24. Dufour N, Clermont O, La Combe B, Messika J, Dion S, Khanna V, Denamur E, Ricard JD, Debarbieux L, ColoColi g. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. J Antimicrob Chemother. 2016;71(11):3072-80. doi: 10.1093/jac/dkw253. PubMed PMID: 27387322.

25. Raz A, Serrano A, Hernandez A, Euler CW, Fischetti VA. Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection. Antimicrob Agents Chemother. 2019;63(7). doi: 10.1128/AAC.00024-19. PubMed PMID: 31010858; PMCID: PMC6591642.

26. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio. 2012;3(2):e00029-12. doi: 10.1128/mBio.00029-12. PubMed PMID: 22396480; PMCID: PMC3302570.

27. Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, Kadioglu A. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666-7. doi: 10.1136/thoraxjnl-2016-209265. PubMed PMID: 28265031; PMCID: PMC5520275.

28. Cao Z, Zhang J, Niu YD, Cui N, Ma Y, Cao F, Jin L, Li Z, Xu Y. Isolation and characterization of a “phiKMV-like” bacteriophage and its therapeutic effect on mink hemorrhagic pneumonia. PLoS One. 2015;10(1):e0116571. doi: 10.1371/journal.pone.0116571. PubMed PMID: 25615639; PMCID: PMC4304800.

29. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L. Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen. Cell Host Microbe. 2017;22(1):38-47 e4. doi: 10.1016/j.chom.2017.06.018. PubMed PMID: 28704651.

30. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci. 2003;82(7):1108-12. doi: 10.1093/ps/82.7.1108. PubMed PMID: 12872966.

31. Christaki E, Giamarellos-Bourboulis EJ. The complex pathogenesis of bacteremia: from antimicrobial clearance mechanisms to the genetic background of the host. Virulence. 2014;5(1):57-65. doi: 10.4161/viru.26514. PubMed PMID: 24067507; PMCID: PMC3916384.

32. Yin S, Huang G, Zhang Y, Jiang B, Yang Z, Dong Z, You B, Yuan Z, Hu F, Zhao Y, Peng Y. Phage Abp1 Rescues Human Cells and Mice from Infection by Pan-Drug Resistant Acinetobacter Baumannii. Cell Physiol Biochem. 2017;44(6):2337-45. doi: 10.1159/000486117. PubMed PMID: 29258062.

33. Schneider G, Szentes N, Horvath M, Dorn A, Cox A, Nagy G, Doffkay Z, Maroti G, Rakhely G, Kovacs T. Kinetics of Targeted Phage Rescue in a Mouse Model of Systemic Escherichia coli K1. Biomed Res Int. 2018;2018:7569645. doi: 10.1155/2018/7569645. PubMed PMID: 30105246; PMCID: PMC6076946.

34. Horvath M, Kovacs T, Koderivalappil S, Abraham H, Rakhely G, Schneider G. Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates. Sci Rep. 2020;10(1):5891. doi: 10.1038/s41598-020-62691-8. PubMed PMID: 32246126; PMCID: PMC7125228.

35. Kaabi SAG, Musafer HK. An experimental mouse model for phage therapy of bacterial pathogens causing bacteremia. Microb Pathog. 2019;137:103770. doi: 10.1016/j.micpath.2019.103770. PubMed PMID: 31586662.

36. Alvi IA, Asif M, Tabassum R, Aslam R, Abbas Z, Rehman SU. RLP, a bacteriophage of the family Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch Virol. 2020;165(6):1289-97. doi: 10.1007/s00705-020-04601-x. PubMed PMID: 32246283.

37. Lin YW, Chang RY, Rao GG, Jermain B, Han ML, Zhao JX, Chen K, Wang JP, Barr JJ, Schooley RT, Kutter E, Chan HK, Li J. Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study. Clin Microbiol Infect. 2020;26(9):1229-35. doi: 10.1016/j.cmi.2020.04.039. PubMed PMID: 32387436.

38. Heselpoth RD, Euler CW, Schuch R, Fischetti VA. Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria. Antimicrob Agents Chemother. 2019;63(6). doi: 10.1128/AAC.00342-19. PubMed PMID: 30962344; PMCID: PMC6535517.

39. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 2015;59(4):1983-91. doi: 10.1128/AAC.04641-14. PubMed PMID: 25605353; PMCID: PMC4356752.

40. Yehl K, Lemire S, Yang AC, Ando H, Mimee M, Torres MT, de la Fuente-Nunez C, Lu TK. Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis. Cell. 2019;179(2):459-69 e9. doi: 10.1016/j.cell.2019.09.015. PubMed PMID: 31585083; PMCID: PMC6924272.

41. Chadha P, Katare OP, Chhibber S. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog. 2016;99:68-77. doi: 10.1016/j.micpath.2016.08.001. PubMed PMID: 27498362.

42. Nishikawa H, Yasuda M, Uchiyama J, Rashel M, Maeda Y, Takemura I, Sugihara S, Ujihara T, Shimizu Y, Shuin T, Matsuzaki S. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch Virol. 2008;153(3):507-15. doi: 10.1007/s00705-007-0031-4. PubMed PMID: 18188500.

43. Rastogi V, Yadav P, Verma A, Pandit JK. Ex vivo and in vivo evaluation of microemulsion based transdermal delivery of E. coli specific T4 bacteriophage: A rationale approach to treat bacterial infection. Eur J Pharm Sci. 2017;107:168-82. doi: 10.1016/j.ejps.2017.07.014. PubMed PMID: 28711712.

44. Verbeken G, Pirnay JP. European regulatory aspects of phage therapy: magistral phage preparations. Curr Opin Virol. 2022;52:24-9. doi: 10.1016/j.coviro.2021.11.005. PubMed PMID: 34801778.

45. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol. 1982;128(2):307-18. doi: 10.1099/00221287-128-2-307. PubMed PMID: 7042903.

46. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2002;2:35. doi: 10.1186/1471-2180-2-35. PubMed PMID: 12453306; PMCID: PMC138797.

47. Singla S, Harjai K, Katare OP, Chhibber S. Bacteriophage-loaded nanostructured lipid carrier: improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae-induced lobar pneumonia. J Infect Dis. 2015;212(2):325-34. doi: 10.1093/infdis/jiv029. PubMed PMID: 25605867.

48. Gibb B, Hyman P, Schneider CL. The Many Applications of Engineered Bacteriophages-An Overview. Pharmaceuticals (Basel). 2021;14(7). doi: 10.3390/ph14070634. PubMed PMID: 34208847; PMCID: PMC8308837.

49. Schuch R, Cassino C, Vila-Farres X. Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance. Front Microbiol. 2022;13:841905. doi: 10.3389/fmicb.2022.841905. PubMed PMID: 35308352; PMCID: PMC8928733.

50. Ardal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N. Antibiotic development - economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18(5):267-74. doi: 10.1038/s41579-019-0293-3. PubMed PMID: 31745330.

51. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S, Krause L, Bibiloni R, Schmitt B, Reuteler G, Brussow H. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology. 2013;443(2):187-96. doi: 10.1016/j.virol.2013.05.022. PubMed PMID: 23755967.

52. Cha K, Oh HK, Jang JY, Jo Y, Kim WK, Ha GU, Ko KS, Myung H. Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo. Front Microbiol. 2018;9:696. doi: 10.3389/fmicb.2018.00696. PubMed PMID: 29755420; PMCID: PMC5932359.

53. Wang Y, Mi Z, Niu W, An X, Yuan X, Liu H, Li P, Liu Y, Feng Y, Huang Y, Zhang X, Zhang Z, Fan H, Peng F, Tong Y, Bai C. Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol. 2016;11:631-41. doi: 10.2217/fmb.16.11. PubMed PMID: 26925593.

54. Soleimani Sasani M, Eftekhar F. Potential of a Bacteriophage Isolated from Wastewater in Treatment of Lobar Pneumonia Infection Induced by Klebsiella pneumoniae in Mice. Curr Microbiol. 2020;77(10):2650-5. doi: 10.1007/s00284-020-02041-z. PubMed PMID: 32451685.

55. Jeon J, Yong D. Two Novel Bacteriophages Improve Survival in Galleria mellonella Infection and Mouse Acute Pneumonia Models Infected with Extensively Drug-Resistant Pseudomonas aeruginosa. Appl Environ Microbiol. 2019;85(9). doi: 10.1128/AEM.02900-18. PubMed PMID: 30824445; PMCID: PMC6495756.

56. Jeon J, Park JH, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol. 2019;19(1):70. doi: 10.1186/s12866-019-1443-5. PubMed PMID: 30940074; PMCID: PMC6444642.

57. Chadha P, Katare OP, Chhibber S. Liposome loaded phage cocktail: Enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns. 2017;43(7):1532-43. doi: 10.1016/j.burns.2017.03.029. PubMed PMID: 28502784.

58. Rahmani R, Zarrini G, Sheikhzadeh F, Aghamohammadzadeh N. Effective Phages as Green Antimicrobial Agents Against Antibiotic-Resistant Hospital Escherichia coli. Jundishapur J Microbiol. 2015;8(2):e17744. doi: 10.5812/jjm.17744. PubMed PMID: 25834712; PMCID: PMC4377167.

59. Kang HW, Kim JW, Jung TS, Woo GJ. wksl3, a New biocontrol agent for Salmonella enterica serovars enteritidis and typhimurium in foods: characterization, application, sequence analysis, and oral acute toxicity study. Appl Environ Microbiol. 2013;79(6):1956-68. doi: 10.1128/AEM.02793-12. PubMed PMID: 23335772; PMCID: PMC3592225.

60. Dufour N, Debarbieux L, Fromentin M, Ricard JD. Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages. Crit Care Med. 2015;43(6):e190-8. doi: 10.1097/CCM.0000000000000968. PubMed PMID: 25803649.

61. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother. 2013;57(12):5961-8. doi: 10.1128/AAC.01596-13. PubMed PMID: 24041900; PMCID: PMC3837875.

62. Chang RYK, Chen K, Wang J, Wallin M, Britton W, Morales S, Kutter E, Li J, Chan HK. Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. Antimicrob Agents Chemother. 2018;62(2). doi: 10.1128/AAC.01714-17. PubMed PMID: 29158280; PMCID: PMC5786808.

63. Chung IY, Sim N, Cho YH. Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities. Antimicrob Agents Chemother. 2012;56(11):5612-7. doi: 10.1128/AAC.00504-12. PubMed PMID: 22908158; PMCID: PMC3486593.

64. Tiwari BR, Kim S, Rahman M, Kim J. Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J Microbiol. 2011;49(6):994-9. doi: 10.1007/s12275-011-1512-4. PubMed PMID: 22203564.

65. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ, Hu J. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med. 2006;17(2):347-55. PubMed PMID: 16391836; PMCID: 16391836.

66. Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV, Teneza-Mora NC, Biswas B, Hall ER. Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections. Antimicrob Agents Chemother. 2016;60(10):5806-16. doi: 10.1128/AAC.02877-15. PubMed PMID: 27431214; PMCID: PMC5038255.

67. Rouse MD, Stanbro J, Roman JA, Lipinski MA, Jacobs A, Biswas B, Regeimbal J, Henry M, Stockelman MG, Simons MP. Impact of Frequent Administration of Bacteriophage on Therapeutic Efficacy in an A. baumannii Mouse Wound Infection Model. Front Microbiol. 2020;11:414. doi: 10.3389/fmicb.2020.00414. PubMed PMID: 32256472; PMCID: PMC7090133.

68. Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol. 2011;60(Pt 2):205-10. doi: 10.1099/jmm.0.018580-0. PubMed PMID: 20965914.

69. Sarhan WA, Azzazy HM. Apitherapeutics and phage-loaded nanofibers as wound dressings with enhanced wound healing and antibacterial activity. Nanomedicine (Lond). 2017;12(17):2055-67. doi: 10.2217/nnm-2017-0151. PubMed PMID: 28805554.

70. Bull JJ, Otto G, Molineux IJ. In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob Agents Chemother. 2012;56(2):949-54. doi: 10.1128/AAC.05842-11. PubMed PMID: 22106213; PMCID: PMC3264239.

71. Gurney J, Brown SP, Kaltz O, Hochberg ME. Steering Phages to Combat Bacterial Pathogens. Trends Microbiol. 2020;28(2):85-94. doi: 10.1016/j.tim.2019.10.007. PubMed PMID: 31744662; PMCID: PMC6980653.

72. Vikram A, Woolston J, Sulakvelidze A. Phage Biocontrol Applications in Food Production and Processing. Curr Issues Mol Biol. 2021;40:267-302. doi: 10.21775/cimb.040.267. PubMed PMID: 32644048.

73. Reynaud A, Cloastre L, Bernard J, Laveran H, Ackermann HW, Licois D, Joly B. Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Veterinary Microbiology. 1992;30(2-3):203-12. doi: 10.1016/0378-1135(92)90114-9.

74. Jamalludeen N, Johnson RP, Shewen PE, Gyles CL. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet Microbiol. 2009;136(1-2):135-41. doi: 10.1016/j.vetmic.2008.10.021. PubMed PMID: 19058927.

75. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One. 2012;7(10):e47742. doi: 10.1371/journal.pone.0047742. PubMed PMID: 23082205; PMCID: PMC3474789.

76. Matsuda T, Freeman TA, Hilbert DW, Duff M, Fuortes M, Stapleton PP, Daly JM. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery. 2005;137(6):639-46. doi: 10.1016/j.surg.2005.02.012. PubMed PMID: 15933632.

77. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother. 2011;55(4):1358-65. doi: 10.1128/AAC.01123-10. PubMed PMID: 21245450; PMCID: PMC3067190.

78. Vinner GK, Rezaie-Yazdi Z, Leppanen M, Stapley AGF, Leaper MC, Malik DJ. Microencapsulation of Salmonella-Specific Bacteriophage Felix O1 Using Spray-Drying in a pH-Responsive Formulation and Direct Compression Tableting of Powders into a Solid Oral Dosage Form. Pharmaceuticals (Basel). 2019;12(1). doi: 10.3390/ph12010043. PubMed PMID: 30909381; PMCID: PMC6469172.

79. Alam M, Akhter MZ, Yasmin M, Ahsan CR, Nessa J. Local bacteriophage isolates showed anti- Escherichia coli O157:H7 potency in an experimental ligated rabbit ileal loop model. Can J Microbiol. 2011;57(5):408-15. doi: 10.1139/W11-020. PubMed PMID: 21542784.

80. Abdulamir AS, Jassim SA, Abu Bakar F. Novel approach of using a cocktail of designed bacteriophages against gut pathogenic E. coli for bacterial load biocontrol. Ann Clin Microbiol Antimicrob. 2014;13:39. doi: 10.1186/s12941-014-0039-z. PubMed PMID: 25062829; PMCID: PMC4222638.

81. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng. 2005;100(3):280-7. doi: 10.1263/jbb.100.280. PubMed PMID: 16243277.

82. Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45. doi: 10.1016/s1473-3099(18)30482-1.

83. Sarker SA, McCallin S, Barretto C, Berger B, Pittet AC, Sultana S, Krause L, Huq S, Bibiloni R, Bruttin A, Reuteler G, Brussow H. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology. 2012;434(2):222-32. doi: 10.1016/j.virol.2012.09.002. PubMed PMID: 23102968.

84. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005;49(7):2874-8. doi: 10.1128/AAC.49.7.2874-2878.2005. PubMed PMID: 15980363; PMCID: PMC1168693.

85. Law N, Logan C, Yung G, Furr CL, Lehman SM, Morales S, Rosas F, Gaidamaka A, Bilinsky I, Grint P, Schooley RT, Aslam S. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665-8. doi: 10.1007/s15010-019-01319-0. PubMed PMID: 31102236.

86. Aslam S, Courtwright AM, Koval C, Lehman SM, Morales S, Furr CL, Rosas F, Brownstein MJ, Fackler JR, Sisson BM, Biswas B, Henry M, Luu T, Bivens BN, Hamilton T, Duplessis C, Logan C, Law N, Yung G, Turowski J, Anesi J, Strathdee SA, Schooley RT. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019;19(9):2631-9. doi: 10.1111/ajt.15503. PubMed PMID: 31207123; PMCID: PMC6711787.

87. Maddocks S, Fabijan AP, Ho J, Lin RCY, Ben Zakour NL, Dugan C, Kliman I, Branston S, Morales S, Iredell JR. Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema Caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019;200(9):1179-81. doi: 10.1164/rccm.201904-0839LE. PubMed PMID: 31437402.

88. Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014;4(2):66-73. PubMed PMID: 25356373; PMCID: PMC4212884.

89. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017;61(10). doi: 10.1128/AAC.00954-17. PubMed PMID: 28807909; PMCID: PMC5610518.

90. Ujmajuridze A, Chanishvili N, Goderdzishvili M, Leitner L, Mehnert U, Chkhotua A, Kessler TM, Sybesma W. Adapted Bacteriophages for Treating Urinary Tract Infections. Front Microbiol. 2018;9:1832. doi: 10.3389/fmicb.2018.01832. PubMed PMID: 30131795; PMCID: PMC6090023.

91. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F, Bourdin G, McCallin S, Ngom-Bru C, Neville T, Akter M, Huq S, Qadri F, Talukdar K, Kassam M, Delley M, Loiseau C, Deng Y, El Aidy S, Berger B, Brussow H. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine. 2016;4:124-37. doi: 10.1016/j.ebiom.2015.12.023. PubMed PMID: 26981577; PMCID: PMC4776075.

92. Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, Francois PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017;21(1):129. doi: 10.1186/s13054-017-1709-y. PubMed PMID: 28583189; PMCID: PMC5460490.

93. Aleshkin AV, Ershova ON, Volozhantsev NV, Svetoch EA, Popova AV, Rubalskii EO, Borzilov AI, Aleshkin VA, Afanas’ev SS, Karaulov AV, Galimzyanov KM, Rubalsky OV, Bochkareva SS. Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Bacteriophage. 2016;6(4):e1251379. doi: 10.1080/21597081.2016.1251379. PubMed PMID: 28090384; PMCID: PMC5221749.

94. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x. PubMed PMID: 19673983.

95. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009;18(6):237-8, 40-3. doi: 10.12968/jowc.2009.18.6.42801. PubMed PMID: 19661847.

96. Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, Khalifa L, Rimon A, Yerushalmy O, Bader R, Amit S, Coppenhagen-Glazer S, Henry M, Quinones J, Malagon F, Biswas B, Moses AE, Merril G, Schooley RT, Brownstein MJ, Weil YA, Hazan R. Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination. Clin Infect Dis. 2019;69(11):2015-8. doi: 10.1093/cid/ciz222. PubMed PMID: 30869755.

97. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Gorski A, Adamia R. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res. 2011;28(4):934-7. doi: 10.1007/s11095-010-0313-5. PubMed PMID: 21063753.

98. Fowler VG, Jr., Das AF, Lipka-Diamond J, Schuch R, Pomerantz R, Jauregui-Peredo L, Bressler A, Evans D, Moran GJ, Rupp ME, Wise R, Corey GR, Zervos M, Douglas PS, Cassino C. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. J Clin Invest. 2020;130(7):3750-60. doi: 10.1172/JCI136577. PubMed PMID: 32271718; PMCID: PMC7324170.